{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:05:35Z","timestamp":1790975135463,"version":"4.1.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011264","name":"FP7 People: Marie-Curie Actions","doi-asserted-by":"publisher","award":["316940"],"award-info":[{"award-number":["316940"]}],"id":[{"id":"10.13039\/100011264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["DKAA GBS1870"],"award-info":[{"award-number":["DKAA GBS1870"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Vaccination with Vi capsular polysaccharide (Vi-PS) or protein-Vi typhoid conjugate vaccine (TCV) can protect adults against <jats:italic>Salmonella<\/jats:italic> Typhi infections. TCVs offer better protection than Vi-PS in infants and may offer better protection in adults. Potential reasons for why TCV may be superior in adults are not fully understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>Here, we immunized wild-type (WT) mice and mice deficient in IgG or IgM with Vi-PS or TCVs (Vi conjugated to tetanus toxoid or CRM197) for up to seven months, with and without subsequent challenge with Vi-expressing <jats:italic>Salmonella<\/jats:italic> Typhimurium. Unexpectedly, IgM or IgG alone were similarly able to reduce bacterial burdens in tissues, and this was observed in response to conjugated or unconjugated Vi vaccines and was independent of antibody being of high affinity. Only in the longer-term after immunization (&amp;gt;5 months) were differences observed in tissue bacterial burdens of mice immunized with Vi-PS or TCV. These differences related to the maintenance of antibody responses at higher levels in mice boosted with TCV, with the rate of fall in IgG titres induced to Vi-PS being greater than for TCV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Therefore, Vi-specific IgM or IgG are independently capable of protecting from infection and any superior protection from vaccination with TCV in adults may relate to responses being able to persist better rather than from differences in the antibody isotypes induced. These findings suggest that enhancing our understanding of how responses to vaccines are maintained may inform on how to maximize protection afforded by conjugate vaccines against encapsulated pathogens such as <jats:italic>S<\/jats:italic>. Typhi.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1139329","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T17:07:59Z","timestamp":1679591279000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses"],"prefix":"10.3389","volume":"14","author":[{"given":"Si\u00e2n E.","family":"Jossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Arcuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej","family":"Alshayea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby R.","family":"Persaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Marcial-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Di Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"P\u00e9rez-Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Pillaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will M.","family":"Channell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Schager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Lamerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte N.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Goodall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Haneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas J.","family":"B\u00e4umler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy H.","family":"Jackson-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Michael","family":"Toellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calman A.","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian R.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Micoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam F.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.04.022","article-title":"Typhoid vaccines: WHO position paper, march 2018 - recommendations","volume":"37","year":"2019","journal-title":"Vaccine"},{"key":"B2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13756-019-0673-5","article-title":"Bacterial pathogens and resistance causing community acquired paediatric bloodstream infections in low- and middle-income countries: a systematic review and meta-analysis","volume":"8","author":"Droz","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807521","article-title":"A cluster-randomized effectiveness trial of vi typhoid vaccine in India","volume":"361","author":"Sur","year":"2009","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92266-K","article-title":"Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial","volume":"336","author":"Levine","year":"1990","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91910-M","article-title":"Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine","volume":"338","author":"Simanjuntak","year":"1991","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)09001-1","article-title":"Typhoid fever in children aged less than 5 years","volume":"354","author":"Sinha","year":"1999","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.06.039818","article-title":"A study of typhoid fever in five Asian countries: disease burden and implications for controls","volume":"86","author":"Ochiai","year":"2008","journal-title":"Bull World Health Organ."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.015","article-title":"Effectiveness of vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan","volume":"30","author":"Khan","year":"2012","journal-title":"Vaccine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.01.001","article-title":"Evaluation of immune responses to an oral typhoid vaccine, Ty21a, in children from 2 to 5 years of age in Bangladesh","volume":"32","author":"Bhuiyan","year":"2014","journal-title":"Vaccine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.11.051","article-title":"Duration of vi antibodies in participants vaccinated with typhim vi (Typhoid vi polysaccharide vaccine) in an area not endemic for typhoid fever","volume":"28","author":"Froeschle","year":"2010","journal-title":"Vaccine"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001261.pub4","volume-title":"Vaccines for preventing typhoid fever","author":"Milligan","year":"2018"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00532-10","article-title":"The vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-vi, and is compatible with routine infant vaccines","volume":"18","author":"Thiem","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31812565bc","article-title":"Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings","volume":"26","author":"Zhou","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(94)90194-5","article-title":"Clinical and serological responses following primary and booster immunization with salmonella typhi vi capsular polysaccharide vaccines","volume":"12","author":"Keitel","year":"1994","journal-title":"Vaccine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12583","article-title":"Specific and cross-reactive plasmablast response in humans after primary and secondary immunization with vi capsular polysaccharide typhoid vaccine","volume":"86","author":"Pakkanen","year":"2017","journal-title":"Scand J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1117715","article-title":"Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph) in Indian children: School based cluster randomized study","volume":"12","author":"Mitra","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.038","article-title":"Safety and immunogenicity of a vi-DT typhoid conjugate vaccine: Phase I trial in healthy Filipino adults and children","volume":"36","author":"Capeding","year":"2018","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211784","article-title":"Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine","volume":"14","author":"Medise","year":"2019","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025398","article-title":"Safety, immunogenicity and dose ranging of a new vi-CRM(1)(9)(7) conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults","volume":"6","author":"van Damme","year":"2011","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905047","article-title":"Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal","volume":"381","author":"Shakya","year":"2019","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035916","article-title":"Safety and efficacy of a typhoid conjugate vaccine in Malawian children","volume":"385","author":"Patel","year":"2021","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1103","article-title":"Typhoid vaccine acceleration consortium Malawi: A phase III, randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children in Blantyre, Malawi","volume":"68","author":"Meiring","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B24","volume-title":"Take on typhoid [Internet]","author":"Neuzil","year":"2020"},{"key":"B25","volume-title":"Typbar TCV\u00ae from bharat biotech, world\u2019s first typhoid conjugate vaccine prequalified by WHO [press release]","year":"2018"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189100","article-title":"The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against salmonella typhi","volume":"12","author":"Arcuri","year":"2017","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002131","article-title":"A salmonella typhimurium-typhi genomic chimera: a model to study vi polysaccharide capsule function in vivo","volume":"7","author":"Jansen","year":"2011","journal-title":"PloS Pathog"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103166","article-title":"The capsular polysaccharide vi from salmonella typhi is a B1b antigen","volume":"189","author":"Marshall","year":"2012","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00172-09","article-title":"The capsule-encoding viaB locus reduces intestinal inflammation by a salmonella pathogenicity island 1-independent mechanism","volume":"77","author":"Haneda","year":"2009","journal-title":"Infect Immun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.9b05107","article-title":"Development of a specific and sensitive HPAEC-PAD method for quantification of vi polysaccharide applicable to other polysaccharides containing amino uronic acids","volume":"92","author":"Giannelli","year":"2020","journal-title":"Anal Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.02.042","article-title":"Determination of free polysaccharide in vi glycoconjugate vaccine against typhoid fever","volume":"139","author":"Giannelli","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)00078-7","article-title":"Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme","volume":"102","author":"Muramatsu","year":"2000","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.7892607","article-title":"Switch transcripts in immunoglobulin class switching","volume":"267","author":"Lorenz","year":"1995","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.10.4776","article-title":"Enhanced b-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM","volume":"160","author":"Boes","year":"1998","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.11.022","article-title":"Vi-CRM 197 as a new conjugate vaccine against salmonella typhi","volume":"29","author":"Micoli","year":"2011","journal-title":"Vaccine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02379-17","article-title":"IgG responses to porins and lipopolysaccharide within an outer membrane-based vaccine against nontyphoidal salmonella develop at discordant rates","volume":"9","author":"Schager","year":"2018","journal-title":"mBio"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0812431106","article-title":"The porin OmpD from nontyphoidal salmonella is a key target for a protective B1b cell antibody response","volume":"106","author":"Gil-Cruz","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI33998","article-title":"The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of salmonella in African children","volume":"118","author":"MacLennan","year":"2008","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.4049\/jimmunol.1000284","article-title":"Absent bactericidal activity of mouse serum against invasive African nontyphoidal Salmonella results from impaired complement function but not a lack of antibody","volume":"186","author":"Siggins","year":"2011","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700952","article-title":"IgG1 is required for optimal protection after immunization with the purified porin OmpD from salmonella typhimurium","volume":"199","author":"Zhang","year":"2017","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.7.3393","article-title":"Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides undergo normal isotype switching after immunization with polysaccharide-protein conjugate vaccines","volume":"161","author":"Shapiro","year":"1998","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2013.845529","article-title":"Development of vi conjugate \u2013 a new generation of typhoid vaccine","volume":"12","author":"Szu","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.08.027","article-title":"Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials","volume":"25","author":"Fraser","year":"2007","journal-title":"Vaccine"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.046","article-title":"Immune suppression induced by vi capsular polysaccharide is overcome by vi-DT conjugate vaccine","volume":"30","author":"An","year":"2012","journal-title":"Vaccine"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.5.2303","article-title":"Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific b cell activation","volume":"183","author":"Toellner","year":"1996","journal-title":"J Exp Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.8.1193","article-title":"T Helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching","volume":"187","author":"Toellner","year":"1998","journal-title":"J Exp Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.6.813","article-title":"Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival","volume":"192","author":"Sze","year":"2000","journal-title":"J Exp Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00255-2","article-title":"Effectiveness of typhoid conjugate vaccine against culture-confirmed salmonella enterica serotype typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study","volume":"9","author":"Yousafzai","year":"2021","journal-title":"Lancet Glob Health"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2310\/7060.2005.12604","article-title":"Combined typhoid fever and hepatitis a vaccine: Comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years","volume":"12","author":"Overbosch","year":"2006","journal-title":"J Travel Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005857117","article-title":"Short vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long vi-CRM197 conjugate vaccine","volume":"117","author":"Micoli","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2165\/00063030-200115001-00002","article-title":"Comparative tolerability and immunogenicity of TypherixTM or typhim vi\u2122 in healthy adults","volume":"15","author":"Lebacq","year":"2001","journal-title":"BioDrugs"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2011.609554","article-title":"The design of semi-synthetic and synthetic glycoconjugate vaccines","volume":"6","author":"Costantino","year":"2011","journal-title":"Expert Opin Drug Discovery"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.11.108","article-title":"Production of a conjugate vaccine for salmonella enterica serovar typhi from citrobacter vi","volume":"30","author":"Micoli","year":"2012","journal-title":"Vaccine"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201116","article-title":"Vi-specific serological correlates of protection for typhoid fever","volume":"218","author":"Jin","year":"2021","journal-title":"J Exp Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of salmonella typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7010018","article-title":"Complementary role of CD4+ T cells in response to pneumococcal polysaccharide vaccines in humans","volume":"7","author":"Jha","year":"2019","journal-title":"Vaccines (Basel)."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2535","article-title":"A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design","volume":"17","author":"Avci","year":"2011","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-130-9-2277","article-title":"Mechanism of the protective action of anti-salmonella IgM in experimental mouse salmonellosis","volume":"130","author":"Sax\u00e9n","year":"1984","journal-title":"J Gen Microbiol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701348","article-title":"An unmutated IgM response to the vi polysaccharide of salmonella typhi contributes to protective immunity in a murine model of typhoid","volume":"200","author":"Pandya","year":"2018","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/1040841X.2016.1249335","article-title":"Vi capsular polysaccharide: Synthesis, virulence, and application","volume":"43","author":"Hu","year":"2017","journal-title":"Crit Rev Microbiol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1524665113","article-title":"Unique lipid anchor attaches vi antigen capsule to the surface of salmonella enterica serovar typhi","volume":"113","author":"Liston","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145945","article-title":"Differential killing of salmonella enterica serovar typhi by antibodies targeting vi and lipopolysaccharide O:9 antigen","volume":"11","author":"Hart","year":"2016","journal-title":"PloS One"},{"key":"B64","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/s41467-020-14655-9","article-title":"Outer membrane protein size and LPS O-antigen define protective antibody targeting to the salmonella surface","volume":"11","author":"Dom\u00ednguez-Medina","year":"2020","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abj1181","article-title":"Salmonella typhi vi capsule prime-boost vaccination induces convergent and functional antibody responses","volume":"6","author":"Dahora","year":"2021","journal-title":"Sci Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a salmonella typhi vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830180221","article-title":"The half-lives of serum immunoglobulins in adult mice","volume":"18","author":"Vieira","year":"1988","journal-title":"Eur J Immunol"},{"key":"B68","volume-title":"Typhim vi electronic medicines compendium (EMC)","year":""}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1139329\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T17:08:05Z","timestamp":1679591285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1139329\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":68,"alternative-id":["10.3389\/fimmu.2023.1139329"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1139329","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"article-number":"1139329"}}